Mary Looby

194 posts

Mary Looby

Mary Looby

@MaryLoobyPharmD

Critical Care / Anticoagulation Clinical Pharmacy Specialist | CVICU | Inova Heart and Vascular Institute

Falls Church, VA Inscrit le Şubat 2012
370 Abonnements103 Abonnés
Mary Looby retweeté
des_linden
des_linden@des_linden·
“It takes 10 years to become an overnight success.” - marathoners “Hold my beer.” - Molly Seidel #TeamUSA
English
89
1.7K
10.5K
0
Mary Looby
Mary Looby@MaryLoobyPharmD·
@bamardis @ISHLT @bamardis would love to learn more and collaborate on something larger. Are you doing this inpatient or outpatient? We launched our pharmacist-run outpatient IV iron clinic for HF patients about 6 months ago.
English
0
0
1
0
Mary Looby
Mary Looby@MaryLoobyPharmD·
@acweyand Seems that way. I would like more information before seeing such a strong recommendation to move to 3rd, 4th line agents for a disease where UFH and LMWH are well-established in improving outcomes. 🤞 more info soon!
English
1
0
0
0
Shematologist, MD
Shematologist, MD@acweyand·
@bradbumm At this point there is no data on whether heparin may exacerbate the condition so all of the major organization are recommending avoidance out of an abundance of caution.
English
1
0
2
0
Mary Looby
Mary Looby@MaryLoobyPharmD·
In the NEJM article they state low dose heparin (LMWH) DECREASED platelet activation and that PF4 activation was independent of heparin. I’m puzzled by why the authors concluded heparin can’t be used. No SRA to corroborate a functional heparin rxn.
Shematologist, MD@acweyand

I’m addition to a similar clinical picture, patients w/VITT post @AstraZeneca demonstrated PF4 heparin antibodies. It is extremely important to differentiate this from other thrombosis as heparin should NOT be used in these patients. 5/x

English
3
0
3
0
Mary Looby
Mary Looby@MaryLoobyPharmD·
Upstream Xa inhibition preventing thrombin generation proving to be 🔑... dabig failed in VADs and mechanical valves (RE-ALIGN). More potential for Xa inhibitors based on case series in VADs and ongoing PROACT Xa (apix w/ On-X valve). Can we ⬇️ GIB in VADs with this approach?🤞🤞
Palak Shah@PalakShahMD

@YasMoayedi @FilioBillia @sarsch79 @WilcoxHeart @SusanJosephMD @ShelleyZieroth @KevinShahMD @docbhardwaj @JonGrinsteinMD @preventfailure @manreetkanwar @rcogswell_umn The German study used dabigatran which is a direct thrombin inhibitor and showed harm. Apixaban works through a different pathway (Xa inhibitor), which is more important in VADs. @bradbumm ahajournals.org/doi/10.1161/CI…

English
0
1
8
0
Mary Looby
Mary Looby@MaryLoobyPharmD·
Yessss. Felt like we were in a tough spot with RED VELVT signaling we need to use VKA for LVT. Great to have a controlled trial to clarify/correct this. 👏🏻
Yehia Saleh@YehiaSaleh_MD

Happy to share the results of No-LVT @JACCJournals -79 patients with left ventricular thrombi were randomized to rivaroxaban vs warfarin -Rivaroxaban was non-inferior and had faster thrombus resolution in comparison to warfarin. @EchofirstB jacc.org/doi/10.1016/j.…

English
0
0
4
0
Mary Looby
Mary Looby@MaryLoobyPharmD·
Ahhh how did I leave off my old friend and favorite HF cardiologist @PalakShahMD ... newly connected in the twitterverse
English
0
0
0
0
Mary Looby
Mary Looby@MaryLoobyPharmD·
@InovaCareers @IHVInews @InovaHealth is looking for cardiology trained pharmacists to join our established cardiac critical pharmacy team! We've got it all.... cardiogenic shock, HF, durable and temp MCS, PH, txp, and expanding pharmacist-run clinics for endless opportunities.
English
1
5
10
0

Découvrir

@Matt_Dimond1 @JCardFail @coconnormd @ShashankSinhaMD @mpsotka @iyadisseh @JamieLWKennedy @preventfailure